With expanded in-vitro and in-vivo capabilities, Noble Life Sciences can now provide end-to-end preclinical testing services to support antimicrobial drug discovery and development under one roof.

Currently available services include:

In vitro services

• Drug screening to identify lead candidates
• Minimal inhibitory concentration (MIC) analysis against prototypic and drug-resistant gram-positive and gram-negative bacteria.
• Resistance selection and characterization
• Inhibition of biofilm formation
• Mechanism of action determination

In-vivo services

• Pharmacokinetics (PK) / pharmacodynamics (PD) and antimicrobial activity in neutropenic thigh-infection models
• Bacterial sepsis models
• Lung infection models
• Customized models
• Wound infection models
• Surgical infection models
• Biofilm-associated device-related infections

To learn more about how to design an ideal preclinical programme for your antibacterial therapeutic, register for the company’s upcoming webinar ‘Antibacterial Drug Discovery and Development: Designing Ideal Preclinicnal Program’.

This complimentary webinar will take place on 30 May at 3:00pm Eastern Standard Time. It will last 45 minutes. Register by making an enquiry using the contact form.